BACKGROUND: The antidepressant effect of estrogen in women undergoing the menopause transition is hypothesized to be mediated by central nervous system effects of increasing estradiol on mood or through a pathway involving suppression of hot flashes and associated sleep disturbance. Estrogen therapy (ET) and the hypnotic agent zolpidem were selected as interventions in a three-arm, double-blind, placebo-controlled trial to distinguish the effects of estradiol, sleep, and hot flashes on depression. METHODS:Women with depressive disorders, hot flashes, and sleep disturbance were randomly assigned to transdermal 17β-estradiol 0.05 mg/d, zolpidem 10 mg/d, or placebo for 8 wk. Changes in serum estradiol, perceived sleep quality, objectively measured sleep, and hot flashes were examined as predictors of depression improvement [Montgomery-Åsberg Depression Rating Scale (MADRS)] using multivariate linear regression. RESULTS:Seventy-two peri/postmenopausal women with depression disorders were randomized to 17β-estradiol (n = 27), zolpidem (n = 31), or placebo (n = 14). There was no significant difference between groups in depression improvement (overall MADRS decrease 11.8 ± 8.6). Increasing estradiol (P = 0.009) and improved sleep quality (P < 0.001) predicted improved mood in adjusted models but reduced hot flashes (P = 0.99) did not. Post hoc subgroup analyses revealed that the therapeutic effect of increasing estradiol levels on mood was seen in perimenopausal (P = 0.009), but not postmenopausal, women. CONCLUSIONS: For women with menopause-associated depression, improvement in depression is predicted by improved sleep, and among perimenopausal women, by increasing estradiol levels. These results suggest that changes in estradiol and sleep quality, rather than hot flashes, mediate depression during the menopause transition. Therapies targeting insomnia may be valuable in treating menopause-associated depression.
RCT Entities:
BACKGROUND: The antidepressant effect of estrogen in women undergoing the menopause transition is hypothesized to be mediated by central nervous system effects of increasing estradiol on mood or through a pathway involving suppression of hot flashes and associated sleep disturbance. Estrogen therapy (ET) and the hypnotic agent zolpidem were selected as interventions in a three-arm, double-blind, placebo-controlled trial to distinguish the effects of estradiol, sleep, and hot flashes on depression. METHODS:Women with depressive disorders, hot flashes, and sleep disturbance were randomly assigned to transdermal 17β-estradiol 0.05 mg/d, zolpidem 10 mg/d, or placebo for 8 wk. Changes in serum estradiol, perceived sleep quality, objectively measured sleep, and hot flashes were examined as predictors of depression improvement [Montgomery-Åsberg Depression Rating Scale (MADRS)] using multivariate linear regression. RESULTS: Seventy-two peri/postmenopausal women with depression disorders were randomized to 17β-estradiol (n = 27), zolpidem (n = 31), or placebo (n = 14). There was no significant difference between groups in depression improvement (overall MADRS decrease 11.8 ± 8.6). Increasing estradiol (P = 0.009) and improved sleep quality (P < 0.001) predicted improved mood in adjusted models but reduced hot flashes (P = 0.99) did not. Post hoc subgroup analyses revealed that the therapeutic effect of increasing estradiol levels on mood was seen in perimenopausal (P = 0.009), but not postmenopausal, women. CONCLUSIONS: For women with menopause-associated depression, improvement in depression is predicted by improved sleep, and among perimenopausal women, by increasing estradiol levels. These results suggest that changes in estradiol and sleep quality, rather than hot flashes, mediate depression during the menopause transition. Therapies targeting insomnia may be valuable in treating menopause-associated depression.
Authors: Jack D Edinger; Michael H Bonnet; Richard R Bootzin; Karl Doghramji; Cynthia M Dorsey; Colin A Espie; Andrew O Jamieson; W Vaughn McCall; Charles M Morin; Edward J Stepanski Journal: Sleep Date: 2004-12-15 Impact factor: 5.849
Authors: A B Douglass; R Bornstein; G Nino-Murcia; S Keenan; L Miles; V P Zarcone; C Guilleminault; W C Dement Journal: Sleep Date: 1994-03 Impact factor: 5.849
Authors: Jennifer L Gordon; Susan S Girdler; Samantha E Meltzer-Brody; Catherine S Stika; Rebecca C Thurston; Crystal T Clark; Beth A Prairie; Eydie Moses-Kolko; Hadine Joffe; Katherine L Wisner Journal: Am J Psychiatry Date: 2015-01-13 Impact factor: 18.112
Authors: Hsin-Fang Chung; Nirmala Pandeya; Annette J Dobson; Diana Kuh; Eric J Brunner; Sybil L Crawford; Nancy E Avis; Ellen B Gold; Ellen S Mitchell; Nancy F Woods; Joyce T Bromberger; Rebecca C Thurston; Hadine Joffe; Toyoko Yoshizawa; Debra Anderson; Gita D Mishra Journal: Psychol Med Date: 2018-02-12 Impact factor: 7.723
Authors: Jennifer B Dwyer; Awais Aftab; Rajiv Radhakrishnan; Alik Widge; Carolyn I Rodriguez; Linda L Carpenter; Charles B Nemeroff; William M McDonald; Ned H Kalin Journal: Am J Psychiatry Date: 2020-05-27 Impact factor: 18.112
Authors: Hadine Joffe; David P White; Sybil L Crawford; Kristin E McCurnin; Nicole Economou; Stephanie Connors; Janet E Hall Journal: Menopause Date: 2013-09 Impact factor: 2.953